Viral Involvement in Alzheimer's Disease

Area of Science:

• Neuroscience
• Infectious Diseases
• Pathology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid plaques and neurofibrillary tangles.
• AD prevalence is rising globally, with no approved therapeutics despite numerous failed clinical trials.
• The causative agent of AD remains unknown, prompting investigation into potential contributing factors like pathogens.

Purpose of the Study:

• To explore the potential role of human herpes simplex virus-1 (HSV-1) in the pathogenesis of Alzheimer's disease.
• To review evidence linking HSV-1 presence in the brain to AD pathology.
• To discuss the implications of valacyclovir's cognitive effects in AD patients.

Main Methods:

• Review of existing literature on HSV-1, AD, and potential therapeutic interventions.
• Analysis of factors contributing to HSV-1 pathogenicity in the context of neurodegeneration.
• Examination of clinical study findings related to valacyclovir and cognitive function in AD patients.

Main Results:

• Human herpes simplex virus-1 (HSV-1) has been detected in the brains of both AD patients and controls.
• HSV-1 possesses mechanisms that could contribute to AD pathology, including latency, tau phosphorylation, and Aβ accumulation.
• Clinical studies indicate that valacyclovir, an antiviral medication, may improve cognitive function in AD patients.

Conclusions:

• HSV-1 is a potential contributor to Alzheimer's disease pathogenesis.
• Further research is warranted to investigate the causal relationship between HSV-1 and AD.
• Antiviral therapies targeting HSV-1 represent a potential avenue for AD treatment.